Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety and efficacy study of donidalorsen for prophylaxis in hereditary angioedema
MOH_2022-11-17_012185Phase 3Active, not recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of donidalorsen in hereditary angioedema (HAE) (2 arms), sponsored by Horizon Therapeutics. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Nov 2022; status: active, not recruiting.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2022-11-17_012185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-17_012185.